Even those with the most severe cases of hepatitis C could have a future without this virus. New direct-acting antiviral medications for treating hepatitis C continue to bring healing potential to a wide variety of hepatitis C patients.
Most recently, two new studies in the Journal of the American Medical Association show that a combination of direct-acting antivirals – in this case daclatasvir, asunaprevir, and beclabuvir – successfully eradicate the hepatitis C virus, even in patients with severe forms of this disease.
In these studies, hepatitis C patients both with and without compensated cirrhosis (which is severe liver scarring) were included. Even with the more challenging situation of compensated cirrhosis, the medication combination brought sustained virologic responses (SVR) of approximately 90%. In some sub-sets the SVR reached 98%. In other words, almost all patients were cleared of infection with the hepatitis C virus.
These studies demonstrate that today’s hepatitis C treatments are easier to use, since they are all-oral, and successful for the vast majority of patients. Liver failure and liver cancer no longer need to be an inevitable outcome for hepatitis C patients, even those who have already progressed to cirrhosis.
MacGill M. Drugs produce high hepatitis C eradication rates, even in liver-diseased patients. Medical News Today May 6, 2015.